Discover and read the best of Twitter Threads about #esccongress2021

Most recents (7)

1/24 This month’s #EHJCaseReports #tweetorial focuses on percutaneous left atrial appendage occlusion.

Is #LAAO the exact solution for preventing stroke & embolism in #AF pts who can’t tolerate #OAC?
Or, a new problem while seeking a solution?…
🎯 The rationale of #LAAO
🔸 In non-valvular #AF patients, 90% of thrombus is located in the #LAA
🔸 These thrombi embolise to the 🧠 & cause #stroke
🎯 Don't miss the ‘#EHRA_ESC #EAPCI expert consensus document on catheter-based #LAAO –an update’…
#LAA closure devices should be safe, efficent and easy to deploy.

📌 Currently available catheter-based devices for #LAAO have different principles.

A- Plug ➡️ Watchman
B- Pacifier ➡️ Amplatzer Amulet
C- Ligation ➡️ Lariat…
Read 25 tweets
Don’t miss a new accredited #tweetorial launching TOMORROW here on @cardiomet_ce. #Emergencymedicine researcher and devotee of deep understanding of drug mechanism of action @md_pollack will be considering why being #nonsteroidal means better #MRA. Don't miss it! @GoggleDocs
1) Welcome to a #tweetorial where we’ll explore the mechanism of action of mineralocorticoid receptor antagonists (#MRA) & consider why it's so #vogue to be #nonsteroidal. This program is accredited for 0.50 credits for #physicians #nurses #pharmacists. I am @md_pollack. #FOAMed
Read 51 tweets
The @GoggleDocs takeover of @cardiomet_CE continues!

We are 4 UK 🇬🇧 based doctors working across healthcare

Our interests are "what's new, and meaningful in cardiorenal metabolic medicine"

Check out our YouTube channel Image
Yesterday we had key messages from the seminal EMPEROR-Preserved trial✅ & EMPEROR-Pooled analysis✅ presented at the #ESCCongress2021

Today we have key messages from the FIGARO-DKD study & FIDELITY meta-analysis exploring the use of finerenone in T2D & a wide range of CKD Image
Let's start with some background - for starters what in the earth is finerenone?!
Read 26 tweets
... more from the #ESCCongress2021 from the @GoggleDocs #Takeover of the @cardiomet_CE

Next up the EMPEROR-Pooled analysis and some of the questions it asks

How does empagliflozin compare with ARNI (sacubitral/valsartan
EMPEROR-Pooled was a prespecified analysis of the two 'sister' studies

EMPEROR-Reduced Trial…


EMPEROR-Preserved Trial…

With very similar #HeartFailure populations, separated by an ejection fraction cut off of 40%

As you can see

📍Very similar results in terms of the primary and secondary #HeartFailure outcomes.

‼️ Although clear attenuation of benefit seen in pople with higher ejection fractions (EF)
Read 9 tweets
1) Welcome to a new joint-accredited #tweetorial on the highlights of cutting-edge #cardiometabolic research from this years #ESCCongress. We are
@GoggleDocs. Follow this tweetorial to earn FREE 0.75h credit, #physicians #nurses #pharmacists!
#FOAMed #medtwitter
2) This program is intended for healthcare professionals and is supported by educational grants from AstraZeneca, Bayer, Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly Company, Chiesi, and NovoNordisk. See archived programs at
3) Over the next 3 days the @GoggleDocs will be #Takeover with @cardiomet_CE account.

We are four 🇬🇧 based doc working across healthcare.

Our interests are "what's new, and meaning full in cardio-renal metabolic medicine"

Check out our YouTube channel
Read 16 tweets
CardioMEMS. Expensive, invasive device. Initial trial contaminated. FDA approves & it sells. Definitive trial now completed yrs later. No sig benefit. However, authors, look only at pre-COVID results, claim benefit, conclude it's worthwhile. #ESCcongress…
Authors write: 'In conclusion, haemodynamic-guided management
across spectrum of ejection fraction & symptom severity was safe but did not reduce a composite of mortality and total heart failure events.” This seems very straightforward. We should stop using it. #ESCCongress2021
Then they say… "in a pre-COVID-19 analysis, a benefit of haemodynamic-guided management on the primary outcome, driven by a decrease in heart failure hospitalisations, was shown… supporting benefits of haemodynamic-guided management in patients with chronic heart failure."
Read 7 tweets
Remarkable win streak for SGLT2i drugs continues…now specifically for heart failure with preserved ejection fraction (HFpEF), where effective therapies are scarce. Empagloflozin benefits one of every ~30 people treated over median of 26 mos.… #ESCCongress
What gives me confidence about the finding is it is consistent w/what we have seen in subgroups of other studies, but not yet in a dedicated trial. Kudos @JavedButler1 Stefan Anker and team. This is truly a landmark in heart failure care. #ESCCongress2021 #ESCcongress @escardio
@JavedButler1 @escardio Another notable about this EMPEROR-Preserved trial… empaglifozin won across a range of outcomes, across all the subgroups (incl people w/o diabetes), and w/o evidence of safety issues (more serious safety issues in the placebo group). Very welcome set of findings. #ESCcongress
Read 6 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!